GSKCH Stock Overview
GlaxoSmithKline Consumer Healthcare Pakistan Limited engages in the research and development, manufacture, marketing, and sale of consumer healthcare products primarily in Pakistan.
GlaxoSmithKline Consumer Healthcare Pakistan Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||PK₨234.00|
|52 Week High||PK₨303.96|
|52 Week Low||PK₨210.10|
|1 Month Change||-7.49%|
|3 Month Change||-10.77%|
|1 Year Change||3.38%|
|3 Year Change||23.97%|
|5 Year Change||-20.14%|
|Change since IPO||259.70%|
Recent News & Updates
|GSKCH||PK Personal Products||PK Market|
Return vs Industry: GSKCH exceeded the PK Personal Products industry which returned -21% over the past year.
Return vs Market: GSKCH exceeded the PK Market which returned -9.9% over the past year.
|GSKCH Average Weekly Movement||3.8%|
|Personal Products Industry Average Movement||6.0%|
|Market Average Movement||5.7%|
|10% most volatile stocks in PK Market||8.8%|
|10% least volatile stocks in PK Market||3.6%|
Stable Share Price: GSKCH is less volatile than 75% of PK stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: GSKCH's weekly volatility (4%) has been stable over the past year.
About the Company
GlaxoSmithKline Consumer Healthcare Pakistan Limited engages in the research and development, manufacture, marketing, and sale of consumer healthcare products primarily in Pakistan. The company offers products in the areas of pain relief under the Panadol and IODEX brands; oral health under the Sensodyne and Parodontax brand names; respiratory health under the Panadol CF, Sancos, T-Day, Tandegyl, and Actified brands; nutrition and gastrointestinal health under the CaC-1000 PLUS, ENO, and Horlicks brand names; and skin health under the Physiogel, Hydrozole, SunBlock 60, Lamisil, Acne Aid, Duofilm, Brevoxyl, and Oilatum brands. It also exports its products.
GlaxoSmithKline Consumer Healthcare Pakistan Fundamentals Summary
|GSKCH fundamental statistics|
Is GSKCH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GSKCH income statement (TTM)|
|Cost of Revenue||PK₨17.51b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||18.23|
|Net Profit Margin||8.83%|
How did GSKCH perform over the long term?See historical performance and comparison
Is GlaxoSmithKline Consumer Healthcare Pakistan undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GSKCH (PKR234) is trading above our estimate of fair value (PKR9.37)
Significantly Below Fair Value: GSKCH is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GSKCH is good value based on its PE Ratio (12.8x) compared to the Asian Personal Products industry average (20.9x).
PE vs Market: GSKCH is poor value based on its PE Ratio (12.8x) compared to the PK market (5.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GSKCH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GSKCH is overvalued based on its PB Ratio (4.1x) compared to the XA Personal Products industry average (1.8x).
How is GlaxoSmithKline Consumer Healthcare Pakistan forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GlaxoSmithKline Consumer Healthcare Pakistan has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has GlaxoSmithKline Consumer Healthcare Pakistan performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GSKCH has a high level of non-cash earnings.
Growing Profit Margin: GSKCH's current net profit margins (8.8%) are higher than last year (6.4%).
Past Earnings Growth Analysis
Earnings Trend: GSKCH's earnings have grown by 19.5% per year over the past 5 years.
Accelerating Growth: GSKCH's earnings growth over the past year (69.1%) exceeds its 5-year average (19.5% per year).
Earnings vs Industry: GSKCH earnings growth over the past year (69.1%) exceeded the Personal Products industry 11%.
Return on Equity
High ROE: GSKCH's Return on Equity (31.8%) is considered high.
How is GlaxoSmithKline Consumer Healthcare Pakistan's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: GSKCH's short term assets (PKR10.0B) exceed its short term liabilities (PKR6.9B).
Long Term Liabilities: GSKCH's short term assets (PKR10.0B) exceed its long term liabilities (PKR294.3M).
Debt to Equity History and Analysis
Debt Level: GSKCH has more cash than its total debt.
Reducing Debt: Insufficient data to determine if GSKCH's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: GSKCH's debt is well covered by operating cash flow (1386.1%).
Interest Coverage: GSKCH earns more interest than it pays, so coverage of interest payments is not a concern.
What is GlaxoSmithKline Consumer Healthcare Pakistan current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GSKCH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GSKCH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GSKCH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GSKCH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: GSKCH is not paying a notable dividend for the PK market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GSKCH has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Farhan Muhammad Haroon serves as Chief Executive Officer and Executive Director at GlaxoSmithKline Consumer Healthcare Pakistan Limited since April 1, 2021. Mr. Haroon served as Chief Financial Officer...
Experienced Management: GSKCH's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Experienced Board: GSKCH's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
GlaxoSmithKline Consumer Healthcare Pakistan Limited's employee growth, exchange listings and data sources
- Name: GlaxoSmithKline Consumer Healthcare Pakistan Limited
- Ticker: GSKCH
- Exchange: KASE
- Founded: 2015
- Industry: Personal Products
- Sector: Household
- Implied Market Cap: PK₨27.391b
- Shares outstanding: 117.05m
- Website: https://www.pk-consumerhealthcare.gsk.com
Number of Employees
- GlaxoSmithKline Consumer Healthcare Pakistan Limited
- 35, Dockyard Road
- West Wharf
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/16 00:00|
|End of Day Share Price||2022/05/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.